Form D · Other

EMMAC Life Sciences Ltd

London, X0 · CIK 0001789520

Offering snapshot reported Mar 5, 2021 · SEC filing

Reported sold
$251K
Offering amount: $251K
Investors reported
3
Form D · investor count
Minimum accepted
$69.7K
Reported outside-investor minimum
First sale
Feb 22, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 5, 2021Initial$250,884No comparison3SEC filing
Jan 15, 2021Initial$9,426,015No comparison10SEC filing
Jan 31, 2020Initial$5,327,995No comparison8SEC filing
Jan 27, 2020Initial$910,800No comparison10SEC filing
Jan 27, 2020Initial$12,518,820No comparison8SEC filing

Offering details

Securities
Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-391385
Items 11 and 13 amounts have been converted from British pounds to US dollars at a rate of $1.3938 per British pound, using the Bank of England daily spot rate on Mar 1/21.
Convertible debentures

Source: Form D, filed Mar 5, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Lorne Abony Director
Antonio Costanzo Director, Executive
Thomas Ellen Director, Executive
Edward Mc Dermott Director, Executive
Barbara Pacchetti Director, Executive
Thomas Rooke Director, Executive
Orr Yarkoni Director

Issuer details

Industry: Other (See others in industry)

Address:
C/O Hill Dickinson Llp The Broadgate Tower, 20 Primrose Street
London, X0, EC2A2EW